{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:34:08Z","timestamp":1779896048176,"version":"3.53.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/cco.0b013e32833ae8b6","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T08:24:02Z","timestamp":1274516642000},"page":"498-502","source":"Crossref","is-referenced-by-count":19,"title":["How to follow-up patients with epithelial ovarian cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Rowan E","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon JS","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R2-17-20210128","first-page":"1551","article-title":"Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients","volume":"25","author":"Fehm","year":"2005","journal-title":"Anticancer Res"},{"key":"R3-17-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/00004728-199307000-00021","article-title":"CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer","volume":"17","author":"Prayer","year":"1993","journal-title":"J Comput Assist Tomogr"},{"issue":"Suppl 2","key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1093\/annonc\/mdn073","article-title":"Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Aebi","year":"2008","journal-title":"Ann Oncol"},{"key":"R5-17-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2008.04.030","article-title":"The role of regular physical examination in the detection of ovarian cancer recurrence","volume":"110","author":"Chan","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R6-17-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ygyno.2006.02.005","article-title":"Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels","volume":"103","author":"Menczer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R7-17-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/gyno.1994.1282","article-title":"An evaluation of routine follow-up of patients treated for endometrial carcinoma","volume":"55","author":"Shumsky","year":"1994","journal-title":"Gynecol Oncol"},{"key":"R8-17-20210128","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/ijgc-00009577-200409000-00029","article-title":"The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients","volume":"14","author":"Tjalma","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"R9-17-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1525-1438.1999.99072.x","article-title":"The experience of long-term hospital follow-up for women who have suffered early stage gynecological cancer: a qualitative interview study","volume":"9","author":"Bradley","year":"1999","journal-title":"Int J Gynecol Cancer"},{"key":"R10-17-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a057754","article-title":"The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer","volume":"1","author":"van der Burg","year":"1990","journal-title":"Ann Oncol"},{"key":"R11-17-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"R13-17-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-8258(03)00051-9","article-title":"Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation","volume":"89","author":"Wilder","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R14-17-20210128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/annonc\/mdn601","article-title":"Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels","volume":"20","author":"Prat","year":"2009","journal-title":"Ann Oncol"},{"key":"R16-17-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2008.12.008","article-title":"Surveillance of patients after initial treatment of ovarian cancer","volume":"71","author":"Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"R17-17-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1148\/radiology.169.3.3186993","article-title":"Peritoneal implants from ovarian tumors: CT findings","volume":"169","author":"Buy","year":"1988","journal-title":"Radiology"},{"key":"R18-17-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2232011081","article-title":"Peritoneal metastases: detection with spiral CT in patients with ovarian cancer","volume":"223","author":"Coakley","year":"2002","journal-title":"Radiology"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2005.02.029","article-title":"(18)F-FDG PET\/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients","volume":"31","author":"Nanni","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"R21-17-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R22-17-20210128","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/IGC.0b013e3181a3cc94","article-title":"Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery","volume":"19","author":"Risum","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"R23-17-20210128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","article-title":"The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Data Collection Project","volume":"112","author":"Fulham","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R24-17-20210128","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-17-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/IGC.0b013e3181a1cc02","article-title":"Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study","volume":"19","author":"Gadducci","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"R26-17-20210128","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2010.01.014","article-title":"Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?","volume":"117","author":"Tanner","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R27-17-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R28-17-20210128","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R29-17-20210128","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdn591","article-title":"The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer","volume":"20","author":"Oksefjell","year":"2009","journal-title":"Ann Oncol"},{"key":"R30-17-20210128","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/jco.2009.27.15_suppl.5522","article-title":"What do patients think about CA-125 monitoring in the follow-up Results from a multicenter trial in 1,060 patients with ovarian cancer.","volume":"27","author":"Oskay-Oezcelik","year":"2009","journal-title":"J Clin Oncol"},{"key":"R31-17-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000292352","article-title":"CA-125 Monitoring in Ovarian Cancer: patient survey responses to the results of the MRC\/EORTC CA-125 Surveillance Trial","volume":"78","author":"Markman","year":"2010","journal-title":"Oncology"},{"key":"R32-17-20210128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2648.2008.04927.x","article-title":"Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review","volume":"65","author":"Lewis","year":"2009","journal-title":"J Adv Nurs"},{"key":"R33-17-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejon.2008.06.002","article-title":"Nurse led telephone follow up in ovarian cancer: a psychosocial perspective","volume":"12","author":"Cox","year":"2008","journal-title":"Eur J Oncol Nurs"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32833ae8b6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:10:51Z","timestamp":1620951051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201009000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32833ae8b6","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}